Control of secondary hyperparathyroidism by vitamin D derivatives

American Journal of Kidney Diseases

Volumn 37, Issue 1 SUPPL. 2, 2001, Pages

  Drüeke, Tilman B ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Chronic renal failure; Hyperparathyroidism; Secondary; Treatment; Vitamin D

Indexed keywords

1 ALPHA HYDROXYVITAMIN D2; 22 OXACALCITRIOL; 24,25 DIHYDROXYCOLECALCIFEROL; 25 HYDROXYVITAMIN D; ALFACALCIDOL; CALCITRIOL; HEXAFLUOROCALCITRIOL; PARACALCITOL; PARATHYROID HORMONE; PHOSPHATE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; PHOSPHATE BLOOD LEVEL; SECONDARY HYPERPARATHYROIDISM;

EID: 0035150626     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.20741     Document Type: Conference Paper

References (20)

1. Vitamin D analogs: From renal bone disease to osteoporosis
2. The use of 1.25-dihydroxyvitamin D3 in early renal failure
3. 1,25(OH)2 vitamin D3 administration in moderate renal failure: A prospective double blind trial
4. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure
5. Low-dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicenter trial)
6. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure
7. Preventing renal bone disease in moderate renal failure with CaCO3 and 25 (OH) vitamin D3
8. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients
9. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure
10. RenaGel (R), a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study
11. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism
12. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidisim in ESRD
13. A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism
14. Pulse oral versus intravenous calcitriol therapy in chronic hemodialysis patients - A prospective and randomized study
15. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: A randomized prospective trial
16. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol
17. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy
18. 1-Alpha-hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: Justification and optimal modalities of administration
19. Effective suppression of parathyroid hormone by 1α-hydroxyvitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism
20. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2